CONTEXT THERAPEUTICS
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
CONTEXT THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2015-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.contexttherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
31.25 M USD
Technology used in webpage:
Viewport Meta Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome Global Site Tag Euro Organization Schema
Similar Organizations
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Allero Therapeutics
Allero Therapeutics is a biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Chromis Therapeutics
Chromis Therapeutics, Inc. (Chromis) is a San Diego-based biopharmaceutical company
Cloudbreak Therapeutics
Cloudbreak Therapeutics is a clinical stage biotechnology company
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Halia Therapeutics
Halia is a preclinical-stage biopharmaceutical company.
HighTide Therapeutics
HighTide Therapeutics is a global clinical-stage biopharmaceutical company.
Purple Biotech
Purple Biotech is an innovative biopharmaceutical drug development company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Metera Pharmaceuticals
Metera Pharmaceuticals is a preclinical stage biotechnology company.
MetrioPharm
MetrioPharm is a clinical stage pharmaceutical development company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
OncoQuest
OncoQuest is a Edmonton-based biopharmaceutical company.
Aralez Pharmaceuticals
Aralez Pharmaceuticals is a global specialty pharmaceutical company.
Rain Therapeutics
Rain Therapeutics is a operator of a clinical stage biotechnology company.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
Vyriad
Vyriad is a clinical stage biopharmaceutical company.
YS Biopharma
YS Biopharma is a global, fully integrated bio-pharmaceutical company.
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
ZSX Medical
ZSX Medical, LLC, is a pre-clinical stage medical device company.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.contexttherapeutics.com Semrush global rank: 5.07 M Semrush visits lastest month: 1.63 K
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Context Therapeutics"
About — Context Therapeutics
Our Purpose. Our purpose is what weaves us together. It is the single most important reason …See details»
Team Bios - Context Therapeutics
She is responsible for all aspects of GMP/GCP/GLP quality for the organization. Erin has more …See details»
Context Therapeutics - LinkedIn
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors.See details»
Context Therapeutics - Crunchbase Company Profile & Funding
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new …See details»
Context Therapeutics Appoints Chief Medical Officer and Vice …
Aug 1, 2024 For more information, please visit www.contexttherapeutics.com or follow the …See details»
Context Therapeutics® Reports Full Year 2021 Operating and …
Mar 23, 2022 For more information, visit www.contexttherapeutics.com. Forward-looking …See details»
Context Therapeutics Announces FDA Clearance of IND …
May 2, 2024 For more information, please visit www.contexttherapeutics.com or follow the …See details»
Management — Context Therapeutics
Meet our Management TeamSee details»
Context Therapeutics - Craft
May 8, 2024 Context Therapeutics is a clinical-stage biopharmaceutical company dedicated …See details»
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Jul 10, 2024 Context Therapeutics Inc. CT-95 is a potentially first-in-class mesothelin x CD3 …See details»
Context Therapeutics Company Overview, Contact Details
May 2, 2024 [email protected]: 50%. [email protected]: …See details»
Contact — Context Therapeutics
Context Therapeutics. 2001 Market Street Suite 3915, Unit 15 Philadelphia, PA 19103. P: …See details»
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Jul 10, 2024 For more information, please visit www.contexttherapeutics.com or follow the …See details»
Context Therapeutics - Overview, News & Similar companies
May 8, 2024 www.contexttherapeutics.com. Revenue $22.2 Million. Stock Symbol CNTX. …See details»
Context Therapeutics Expands Board of Directors
Mar 22, 2021 ONA-XR is a novel, first-in-class complete antagonist of the progesterone …See details»
BioAtla and Context Therapeutics Announce Exclusive Worldwide …
Sep 23, 2024 For more information, please visit www.contexttherapeutics.com or follow the …See details»
Context Therapeutics® Announces Closing of Initial Public
PHILADELPHIA, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (the …See details»
Patients — Context Therapeutics
Summary of Context Therapeutics clinical trials. Enrollment in one of our clinical trials is our …See details»
Context Therapeutics® Reports First Quarter 2022 Operating and ...
May 11, 2022 For more information, visit www.contexttherapeutics.com. Forward-looking …See details»